Novo Nordisk launches trial of pipeline drug CagriSema versus newly approved Zepbound
The launch of this Phase III comparative trial by Novo Nordisk might imply that CagriSema and Zepbound are expected to become direct competitors once Novo Nordisk’s candidate reaches the market.
